Introduction {#S1}
============

Treatment of advanced stage squamous cell carcinoma of larynx and hypopharynx constitutes a challenging situation. Cisplatin-based chemoradiation is an established treatment for selected moderately advanced laryngeal and hypopharyngeal carcinoma, as it may be organ and function sparing [@R01]^-^[@R04].

For recurrent disease, salvage laryngectomy or neck dissection may be available as a curative option for selected patients. However, the complication rate of salvage surgery after chemoradiation is relatively high. Wound healing problems are a well-known consequence of surgery in irradiated patients. Fistula rates of 11-58% after salvage laryngectomy are reported [@R05]^-^[@R11]. Due to further locoregional recurrence after salvage laryngectomy, distant metastases, second primaries and other causes, the 5-year overall survival is in the range of 31-57% [@R12]^-^[@R15]. The literature suffers from heterogeneity as to tumour site, previous therapy and salvage therapy.

Herein, we aim to provide insight into the recurrence pattern after chemoradiation for laryngeal and hypopharyngeal carcinoma and the options for salvage surgery. We were specifically interested in the complications after salvage surgery, with focus on age. Moreover, the outcome of patients after salvage surgery is evaluated.

Materials and methods {#S2}
=====================

Patients {#S2a}
--------

Sixty patients with locoregional disease after chemoradiation were identified from a database of 136 patients with laryngeal or hypopharyngeal squamous cell carcinoma treated by chemoradiation with curative intent between January 1990-April 2010. The hospital charts of these patients were retrospectively reviewed. In all patients response to chemoradiation was evaluated within or at 3 months after treatment, unless patients had died during or shortly after the chemoradiation. Resectability prior to treatment was determined by physical examination, imaging and endoscopy. Approval of the Medical Ethics Committee of the VU University Medical Center in Amsterdam was obtained. Patient and treatment characteristics are shown in [Table I](#T1){ref-type="table"}.

###### 

Patient characteristics of 60 patients with locoregional disease after chemoradiation.

  Variables                                                                             Number   Percentage (%)
  ------------------------------------------------------------------------------------- -------- ----------------
  **Gender**                                                                                     
    Male                                                                                51       85
    Female                                                                              9        15
  **T-stage (prior to chemoradiation)**                                                          
    T2                                                                                  3        5
    T3                                                                                  30       50
    T4                                                                                  27       45
  **N-stage (prior to chemoradiation)**                                                          
    N0                                                                                  15       25
    N1                                                                                  7        12
    N2a                                                                                 3        5
    N2b                                                                                 13       22
    N2c                                                                                 17       28
    N3                                                                                  5        8
  Primary site                                                                                   
    Hypopharynx                                                                         35       58
    Larynx                                                                              25       42
  **Operability**                                                                                
    Unresectable                                                                        4        7
    Organ preservation approach                                                         56       93
  Chemoradiation schedule                                                                        
    Cisplatin IA[^\*^](#T1FN1){ref-type="table-fn"}                                     2        3
    Cisplatin IV[^\*^](#T1FN1){ref-type="table-fn"}                                     24       40
    Cisplatin/5-FU alternating[^\*\*^](#T1FN2){ref-type="table-fn"}                     14       24
    Cisplatin/5-FU sequential [^\*\*\*^](#T1FN3){ref-type="table-fn"}                   13       22
    Cetuximab[^\*\*\*\*^](#T1FN4){ref-type="table-fn"}                                  5        8
    Cetuximab/TPF/Cisplatin or carboplatin[^\*\*\*\*\*^](#T1FN5){ref-type="table-fn"}   2        3

Concurrent four intra-arterial cisplatin (150 mg/m^2^) infusions or three intravenous cisplatin (100 mg/m^2^) infusions. In both schemes patients were radiatedwith 70 Gy irradiation (6-7 weeks);

cisplatin 20 mg/kg and 5-FU 200 mg/kg intravenously in week 1, 4, 7, 10; radiotherapy in week 2, 3, 5, 6, 8, 9, total dose 60 Gy;

cisplatin 100 mg/kg and 5-FU 1000 mg/kg intravenously, 4 courses; followed by 7 weeks radiotherapy, total dose 70 Gy;

weekly cetuximab in combination with 7 weeks radiotherapy, total dose 70 Gy;

2-4 courses of TPF (Docetaxel, Platinum, Fluorouracil), followed by cisplatin or carboplatin with concurrent 70 Gy radiotherapy (7 weeks), in some patients cetuximab was given during this treatment.

We defined chemoradiation as the combined use of cisplatin based chemotherapy and/or targeted therapy and radiotherapy for the primary treatment. Different schemes are used. Fourteen patients were treated according to an alternating scheme (cisplatin 20 mg/kg and 5-FU 200 mg/kg (i.v.) in week 1, 4, 7 and 10; radiotherapy in week 2, 3, 5, 6, 8 and 9, total dose 60 Gy) and 13 according to a sequential scheme (cisplatin 100 mg/kg and 5-FU 1000 mg/kg i.v., 4 courses; followed by 7 weeks radiotherapy, total dose 70 Gy). Twenty-four patients were treated with concomitant intravenous administration of 3 × 100 mg/m^2^ cisplatin on day 1, 22 and 43 with simultaneous radiotherapy. Two patients were treated according to the intra-arterial chemoradiation schedule consisting of four consecutive weekly selective intra-arterial infusions of cisplatin (150 mg/m^2^) followed by intravenous sodium thiosulphate rescue combined with simultaneous radiotherapy. All patients were irradiated daily for 6-7 weeks to a total dose of 70 Gy (2 Gy per fraction, 5-6/week). Two patients were treated according to the concomitant intravenous cisplatin protocol, in combination with cetuximab. Five patients received weekly cetuximab (loading dose 400 mg/m^2^, followed by weekly 250 mg/m^2^) with daily radiotherapy for 7 weeks to a total dose of 70 Gy. Both sides of the neck were radiated in all patients, regardless of the lymph node status.

Definitions {#S2b}
-----------

Postoperative complications were categorised into surgical complications (fistula, infection, necrosis, haemorrhage and chyle leakage), pneumonia and other complications (e.g. spondylodiscitis). Complications were classified as major if they required re-operation.

Statistics {#S2c}
----------

Statistical analysis was performed with SPSS 15.0. Survival rates were calculated with the Kaplan-Meier method, with follow-up intervals calculated from the date of salvage surgery. Univariate analysis of survival parameters was done using the log-rank test. Univariate analyses of complication patterns were assessed by utilizing the χ^2^-test or the independent- samples T-test whenever applicable. Multivariate analysis of survival was performed with Cox regression. A model developed by Tan et al. [@R16] with stratification factors for survival, was applied to our population.

Results {#S3}
=======

After a median follow-up of 25 months (range 0-130 months), 60 patients (44%) had presented with recurrent disease. One-third of the patients with recurrent disease (n = 22) underwent salvage surgery for local, regional or locoregional disease. This is 16% of the total group of patients initially treated by chemoradiation. Twenty-four percent of patients with laryngeal carcinoma vs. 10% of patients with hypopharyngeal carcinoma underwent salvage surgery. Two-thirds of patients (n = 38) were not suitable for salvage surgery because of distant metastases (n = 30), poor general condition of the patient (n = 3), refusal of surgery by the patient (n = 1) or unresectability of the tumour (n = 4).

Of the 6 patients with an initial unresectable tumour, 4 patients developed recurrent disease, which was not statistically different from the organ preservation (initial resectable) group. Two patients developed distant metastases and 2 patients were diagnosed with persistent unresectable local disease. Independent predictors for salvage surgery within the group of 60 patients with recurrent disease, were age younger than 59 years (p = 0.036) and larynx vs. hypopharynx (p = 0.002) in multivariate analyses. Gender, Tand N-stage were not associated with surgery for salvage.

The median interval between radiotherapy and recurrence for the 22 patients was 4 months.

The study population consisted of 19 males and 3 females with a median age of 59 years (range: 40-69 years), with primary tumours in larynx (n = 15) and hypopharynx (n = 7) ([Table II](#T2){ref-type="table"}).

###### 

Patient and salvage surgery characteristics.

  Patient   Gender   Age   T   N    Site          Recurrence     Larynx         ND[^\*^](#T2FN1){ref-type="table-fn"}   Reconstruction   Subsequent reconstruction
  --------- -------- ----- --- ---- ------------- -------------- -------------- --------------------------------------- ---------------- ---------------------------
  1         F        52    4   1    Hypopharynx   Local          Laryngectomy   Bilateral                               FRFF+PM          PM
  2         M        57    3   2b   Larynx        Regional       \-             Unilateral                              PC               
  3         M        64    4   0    Larynx        Local          Laryngectomy   Unilateral                              PM               
  4         M        63    4   0    Larynx        Local          Laryngectomy   Bilateral                               PM               PM
  5         M        62    4   0    Larynx        Local          Laryngectomy   Unilateral                              PM               
  6         M        59    3   2c   Hypopharynx   Regional       \-             Bilateral                               PM               
  7         M        41    3   0    Hypopharynx   Local          Laryngectomy   Unilateral                              PM               
  8         M        55    4   2c   Larynx        Local          Laryngectomy   Bilateral                               PM               
  9         M        67    4   0    Larynx        Local          Laryngectomy   Bilateral                               PM               
  10        M        57    3   2b   Larynx        Local          Laryngectomy   Bilateral                               PM               
  11        M        52    4   3    Hypopharynx   Regional       \-             Unilateral                              PM               
  12        M        49    3   2a   Larynx        Regional       \-             Unilateral                              PC               \$
  13        M        54    4   2c   Larynx        Locoregional   Laryngectomy   Bilateral                               PC               
  14        M        58    2   2b   Hypopharynx   Regional       \-             Unilateral                              PC               
  15        M        53    3   2c   Larynx        Local          Laryngectomy   Bilateral                               PM               
  16        M        55    3   0    Larynx        Local          Laryngectomy   Bilateral                               PM               
  17        M        61    3   2c   Hypopharynx   Regional       \-             Unilateral                              PM               
  18        F        59    3   0    Larynx        Local          Laryngectomy   Bilateral                               PM               
  19        M        69    4   0    Larynx        Local          Laryngectomy   Bilateral                               PM               
  20        F        67    3   1    Larynx        Local          Laryngectomy   Bilateral                               PM               
  21        M        58    4   3    Hypopharynx   Local          Laryngectomy   Bilateral                               PM               
  22        M        64    3   2c   Larynx        Regional       \-             Unilateral                              PM               

1 year after ND: total salvage laryngectomy with FRFF and PM, followed by a second PM for complications. ND: neck dissection; PC: primary closed; PM: pectoralis major flap; FRFF: free radial forearm flap.

Neck dissection was performed in all patients. In 15 patients the salvage operation consisted of a total laryngectomy with unilateral (n = 2) or bilateral (n = 13) neck dissection. In 7 patients the surgery was limited to a neck dissection because the primary was controlled.

Histopathological examination of total laryngectomy with neck dissection showed negative resection margins in 11 patients (74%), close margins in 2 patients (13%) and microscopic positive margins in 2 patients (13%). Of the patients with neck dissection without laryngectomy 6 had negative resection margins (86%) and 1 microscopic positive margins (14%). No difference in histopathological results between the larynx and hypopharynx was found. Of the two patients with positive margins one was treated with postoperative radiotherapy, but he developed a local recurrence for which he received palliative chemotherapy. One of the patients with close margins developed a recurrence at the stoma and oesophagus, and underwent palliative radiotherapy and chemotherapy.

Reconstruction {#S3a}
--------------

The pectoralis major myocutaneous or myofascial pectoralis major (PM) flap was the most often used flap after total laryngectomy with or without pharyngectomy. Primary closure was only possible with smaller defects. With larger defects, when between one-third and three-quarters of the pharyngeal circumference has been resected, reconstruction was performed by utilising a pectoralis major myocutaneous PM flap. A circumferential pharyngeal defect not extending into the chest was free radial forearm flap (FRFF). A myofascial PM flap was also used to reinforce pharyngeal defects [@R17]. The mucosal defect was closed primarily in 9 of the 15 patients (60%), reconstructed with a PM flap in 5 patients, and reconstructed with a free radial forearm flap (FRFF) in 1 patient. A PM flap to prevent wound healing problems was used in 9 of the 15 patients with a total laryngectomy and in 4 of the 7 patients with a neck dissection without laryngectomy.

Postoperative complications {#S3b}
---------------------------

No perioperative death occurred. Postoperative complications were observed in 15 (68%) of the 22 patients ([Table III](#T3){ref-type="table"}). Three patients experienced major complications that required re-operation. This concerned fistula in two patients and a bleeding in one patient that were closed with a (second) PM flap during re-operation. Most of the complications concerned wound healing problems (n = 13; 59%), as fistula (n = 5), wound dehiscence or wound infection (n = 7) or haemorrhage (n = 1). Other complications were pneumonia and spondylodiscitis in 2 patients.

###### 

Postoperative complications for the total salvage surgery group, the group with an opened pharynx vs. the group with a closed pharynx.

  Complications                Total   Pharynx open   Pharynx closed              
  ---------------------------- ------- -------------- ---------------- ------ --- ------
  None                         7       31%            4                27%    3   43%
  Wound healing                13      59%            9                59%    4   57%
  \- Infection or dehiscence   7       31%            5                32%    2   29%
  \- Haemorrhage               1       5%             0                0%     1   14%
  \- Fistula                   5       23%            4                27%    1   14%
  Pneumonia                    1       5%             1                7%     0   0%
  Other                        1       5%             1                7%     0   0%
  Total                        22      100%           15               100%   7   100%

Univariate analysis showed significantly more wound healing problems in patients with excessive alcohol intake (8 of 16 patients (50%) vs. none of 5 patients, p = 0.04). Furthermore, none of the following parameters were predictive for the development of postoperative complications: tobacco use or excessive alcohol intake at the time of presentation for the primary tumour, T- or N-stage, site of the primary tumour and age under the median of 59 years. No significant reduction in overall complications, wound related complications or fistula was found in our group of patients with a PM flap after neck dissection compared to patients with a primarily closed neck dissection.

Survival {#S3c}
--------

Overall, 5-year disease free control rate was 35%, with 5-year locoregional and distant metastases control rates of 54% and 77%, respectively. Five-year overall survival was 27% (median 30 months) ([Fig. 1](#F1){ref-type="fig"}), and disease specific survival was 35% after salvage surgery. For the 38 patients with residual or recurrent disease after chemoradiation who were not suitable for salvage surgery median survival was 12 months. Patients with tumour control (n = 76) had a 5-year survival of 70% (median 96 months) ([Fig. 1](#F1){ref-type="fig"}). In uni- and multivariate analyses no significant predictors for overall survival after salvage surgery were found. Thus, age under or above the median 60 years was not a predictor factor for survival. The model of Tan et al. [@R16] stratified patients with none, one or two of the following predictors for post salvage overall survival: stage IV (vs. other stages) and simultaneous (*vs*. local or regional) failure. When this model was applied to our population, no significant differences between the groups could be found ([Fig. 2](#F2){ref-type="fig"}), although the group with stage IV disease showed a worse overall survival compared to patients with stage II or III disease ([Fig. 3](#F3){ref-type="fig"}).

![Five-year survival after the last treatment (chemoradiation or salvage surgery).](0392-100X-35-162-g001){#F1}

![Survival after salvage surgery with model according to Tan et al. [@R16] Comparison between patients with zero, one or two of the following presalvage predictors: stage IV vs. other stages and simultaneous locoregional vs. local or regional failure. No significant difference between the three groups was found.](0392-100X-35-162-g002){#F2}

![Survival after salvage surgery with model according to Tan et al. [@R16] Comparison between patients initial stage IV vs. initial non-stage IV disease. A trend (p = 0.05) towards a worse survival for patients with initial stage IV disease was found.](0392-100X-35-162-g003){#F3}

With a median length of follow-up after salvage surgery of 26 months (range 6-127 months), recurrent disease was found in 12 of the 22 patients (64%). These recurrences included local and/or regional recurrences in 8 patients and distant metastases in 4 patients. Local recurrences, regional recurrences and distant metastasis developed after a median interval of 6.5 months (range 2.5-14.3), 7.5 months (range 4.4-14,3) and 3.7 months (range 0-28.2) after salvage surgery, respectively.

Discussion {#S4}
==========

In this study, 37% of the patients with local and/or regional recurrences after chemoradiation for a laryngeal or hypopharyngeal tumour underwent salvage surgery, which is similar to rates reported by other authors, 33-66% [@R07] [@R14] [@R16] [@R18]. A larger proportion of patients with recurrent laryngeal than hypopharyngeal tumours underwent salvage surgery. This is in accordance with the report by Esteller et al. [@R18] Independent predictors for salvage surgery within in the group of patients with locoregional failure, were age less than 59 year and larynx primary (*vs*. hypopharynx).

Fifteen patients underwent laryngectomy with neck dissection and 7 patients neck dissection only.

The rates of complications after salvage surgery are known to be high, with wound related complications and especially pharyngocutaneous fistula as a major problem. In this study 23% of patients developed a fistula. Review of the literature shows complication rates of 5-78%, with fistula in 4-73% of the patients ([Table IV](#T4){ref-type="table"}). Studies are difficult to compare, because of lack of homogeneity in patients (tumour site, stage) and in primary treatment (radiotherapy, chemoradiation).

###### 

Previous studies on complications and survival outcome in patients with salvage surgery after chemoradiotherapy for squamous cell carcinoma of the hypopharynx and larynx.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                             Year   N       Site   Comp          Fistula   LR             OS             DSS               Remarks
  --------------------------------------------------- ------ ------- ------ ------------- --------- -------------- -------------- ----------------- ----------------------------------
  Stoeckli [@R07]                                     2000   36      L      28%           14%                                     63% (5 y)         RT and CRT

  Stoeckli [@R07]                                     2000   9       H      40%           11%                                     20% (5 y)         RT and CRT

  Leon [@R14]                                         2001   28      L      21%           17%                      57% (5 y)                        endoresection

  Weber [@R35]                                        2003   75      L      \~59%         \~30%     74% (2 y)      69-71% (2 y)                     

  Ganly [@R26]                                        2005   38      L      53%           32%                                                       

  Clark [@R13]                                        2006   138     L/H    70%\          31%                      31% (5 y)\                       PT: none, RT, CRT
                                                                            (salvage)                              (salvage)                        

  Fung [@R20]                                         2007   14      L                    29%                                                       Interposition graft.\
                                                                                                                                                    ngopharyngectomy defects

  Furuta [@R44]                                       2008   34      L      47% wound     24%                                                       

  Gil [@R05]                                          2009   18      L                    39%                                                       PL/TL, RT and CRT

  Patel [@R06]                                        2009   17      L                    24%                                                       CRT or RT?

  Relic [@R45]                                        2009   16      L/H                  73%                      38% (3 y)                        1 PL

  Tsou [@R08]                                         2010   48      H                    58%                                                       

  Paleri[^\*^](#T4FN1){ref-type="table-fn"} [@R46]    2011   \>350   L                              87% (2 y)      83% (3 y)      91% (2 y)         RT and CRT, PL

  vd Putten [@R15]                                    2011   120     L                              70% (5 y)\     50% (5 y)      58% (5 y)         RT and CRT, TL
                                                                                                    79% (5 y)\                                      
                                                                                                    regional                                        

  Klozar [@R47]                                       2012   208     L/H                  34%                                                       RT and CRT

  Sewnaik [@R48]                                      2012   24      L/H    92%                                                                     

  Patel [@R09]                                        2013   359     L/H                  27%                                                       RT and CRT, primLE

  Li [@R12]                                           2013   100     L                              70% (5 y)                     55-70% (5 y)      RT and CRT, survival

  Basheeth [@R49]                                     2013   45      L/H    44%                                                                     Major complications, N0

  Suzuki [@R50]                                       2013   24      H      33%                                    50% (2 y)                        

  Sayles[^\*^](#T4FN1){ref-type="table-fn"} [@R10]    2014   33 st   L/H                  34%                                                       

  Timmermans [@R31]                                   2014   98      L/H                  26%                                                       RT and CRT, primLE

  Omura [@R51]                                        2014   42      H                                                            40% (3 y)         RT and CRT, ICT

  Powell [@R52]                                       2014   45      L/H                  22%                                                       

  Suslu [@R11]                                        2015   151     L/H                  13%                                                       RT and CRT, ICT

  Sassler [@R30]                                      1995   18      HN     61% major     50%                                                       Sequential CRT

  Newman [@R53]                                       1997   17      HN     35%           20%                                                       

  Lavertu [@R34]                                      1998   26      HN     46%           4%                                                        

  Goodwin [@R37]                                      2000   109     HN     20%           6%                                      Med 21.5 months   PT: surgery, RT, CRT (17%)

  Goodwin[^\*^](#T4FN1){ref-type="table-fn"} [@R37]   2000   1633    HN     39%                                    39% (5 y)                        PT: surgery, RT, CRT

  Agra [@R54]                                         2003   124     HN     78% (CRT)                                                               PT: surgery, RT, CRT

  Gleich [@R55]                                       2004   48      HN                             20% (5 y)                     15% (5 y)         Local recurrence

  Taussky [@R56]                                      2005   17      HN\    76%           24%                      46% (3 y)\                       RT and CRT
                                                                     N                                             13% (5 y)                        

  Morgan [@R57]                                       2007   38      HN     11%           5%                                                        Local compl 23%

  Encinas [@R58]                                      2007   26      HN     31%                                                                     Article not available

  Richey [@R39]                                       2007   38      HN     24%                     42% (2 y)      27-60%\                          
                                                                                                                   (1,2 y)                          

  Tan [@R16]                                          2010   38      HN     63%                                    43% (2 y)\                       
                                                                                                                   37% (5 y)                        

  Inohara [@R36]                                      2010   30      HN     30%           7%                       74-87% (3 y)                     

  Esteller [@R18]                                     2011   32      HN     28%           19%                      34% (5 y)                        

  Simon [@R59]                                        2011   21      HN     33%           10%                                                       

  Leon [@R60]                                         2015   24      HN     63%\                                   26%(5 y)\                        CRT\
                                                                            13%                                    70%(5 y)                         Bioradiotherapy

  Present study                                              22      HN     73%           23%       58% (5 y)      27% (5 y)      36% (5 y)         

  Davidson [@R27]                                     1999   34      N      38%           12%                                                       37% CRT

  Stenson [@R61]                                      2000   69      N      25%           10%                                                       

  Newkirk [@R62]                                      2001   33      N                                                                              13 CRT,20 RT.

  Grabenbauer [@R63]                                  2003   56      N      25%           4%                       44%(5 y)       55%               Planned ND

  Kutler [@R64]                                       2004           N      \~30%                                                                   Only abstract

  Brizel [@R65]                                       2004   52      N      8% major                75% (4 y)      77%(4 y)                         Planned ND in N2-3. survival cCR

  Frank [@R66]                                        2005   39      N      5% surgical                                                             

  vd Putten [@R67]                                    2007   61      N                              79% (5 y)      36% (5 y)                        

  Nouraei [@R68]                                      2008   41      N                              95% (5 y)                     64% (5 y)         Survival hemineck

  Vedrine [@R69]                                      2008   28      N      14% severe                                                              

  Christopoulos [@R70]                                2008   32      N      13%                                                                     

  Lango [@R71]                                        2009   65      N      18%           5%                                                        55%CRT

  Relic [@R45]                                        2009   12      N      8%                                                                      

  Hillel [@R72]                                       2009   41      N      17%                                                                     

  Bremke [@R73]                                       2009   25      N      24%                                                                     

  Goguen [@R28]                                       2010   105     N      37%                                                                     

  Robbins [@R74]                                      2012   30      N                                                            60% (5 y)         SSND, CRT

  Yirbesoglu [@R75]                                   2013   44      N                              71-73% (3 y)   55-64% (3 y)                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Systematic review;

y: year; Com: complications, fistul: fistula, LR: locoregional control rate, OS: overall survival, DSS: disease specific survival, L: larynx, H: hypopharynx, HN: head and neck, N: neck, y: year, DFS: disease free survival, CRT: chemoradiotherapy, RT: radiotherapy, CT: chemotherapy, ND: neck dissection, PT: previous treatment, PL: partial laryngectomy, TL: total laryngectomy, primLE: primary laryngectomy, SSND: super selective neck dissection, st: studies, ICT: induction chemotherapy.

If wound healing problems are likely, pedicled PM flaps are very useful to cover important structures in the neck with well vascularised, non-irradiated tissue. In the present study, in 59% of the patients a PM flap was used for prevention of wound related complications. Unfortunately, no significant reduction in overall complications, wound related complications or fistula was found in our group of patients with a PM flap after neck dissection compared to patients with a primarily closed neck dissection. In our population only patients with considerable postradiation effects who were considered to be prone to wound healing problems underwent reconstruction with PM flap in the neck. Most studies evaluating reconstructive methods are conducted in patients undergoing salvage laryngectomy ([Table V](#T5){ref-type="table"}). Similar to our results, no difference in the incidence of local wound complications or fistula between the groups with and without PM flap was found by Gil et al. [@R05] and Righini et al. [@R19] Although it was an effective technique to prevent major complications, free vascularised tissue reinforcement did not alter the overall fistula rate as compared to when no flap was used, as reported by Fung et al. [@R20] Smith et al. [@R21] reported a significant reduction in fistula formation in patients with as compared to patients without PM flap reconstruction, but the percentage of patients with initial chemoradiation vs. primary surgery was not described. Sayles et al. [@R10] performed a review and meta- analysis of 33 studies, and found only 10% fistula for salvage laryngectomy with onlay flap-reinforced closure compared to 28% fistula for salvage laryngectomy when no flap was used. Recently Paleri et al. [@R22] described in a systematic review of nearly 600 patients a reduced risk of fistula by one-third in patients who have flap reconstruction/ reinforcement. Reconstruction of the mucosal defect using a PM flap may be associated with a higher rate of fistulae as compared to primary closure whereas a PM flap used as layer between mucosa and skin may reduce the risk of fistula formation. According to Righini et al. [@R19], fistula formation in postradiotherapy salvage surgery was reduced from 73% to 13% when a flap was used in the subgroup of patients with diabetes mellitus, a history of vascular disease or a poor nutritional status. Tsoe et al. [@R08] and Withrow et al. [@R23] suggest to reconstruct laryngectomy defects with an ALT (anterolateral thigh) or FRFF flap, as the incidence of fistula was low in their study.

###### 

Comparison of pharyngocutaneous fistula in patients with salvage laryngectomy with and without flap reinforcement. In two studies, besides for reinforcement, the flap was also used to reconstruct pharyngeal defects [@R21] [@R23].

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                            Year   N            Site      Flap         Fistula   WC   Fistula No flap   WC No flap   p       Remarks
  -------------------------------------------------- ------ ------------ --------- ------------ --------- ---- ----------------- ------------ ------- ------------------------------------------------------------------------
  Righini [@R19]                                     2005   60           larynx\   PMMF\        23%\           50%\                           0.06\   Radiotherapy\
                                                                         larynx    PMMF         13%            73%                            0.018   Subgroup: diabetes mellitus, vascular history, poor nutritional status

  Fung [@R20]                                        2007   41           larynx    FVT          29%       0%   30%               15%          n.s.    

  Patel [@R06]                                       2009   17           larynx    PMF          0%             57%                            0.02    (Chemo)radiotherapy

  Gil [@R05]                                         2009   80           larynx    PMMF         27%            24%                            n.s.    PMMF 64% CRT, nonPMMF 25% CRT

  Smith [@R21]                                       2003   223          larynx    PMF          \<1%           23%                                    

  Withrow [@R23]                                     2007   37           larynx    FRFF         18%            50%                                    FRFF 41%CRT, nonFRFF 35%CRT

  Patel [@R09]                                       2013   359          larynx    PMF\         15%\           34%                            0.02\   (Chemo)radiotherapy
                                                                                   FVT          25%                                           0.07    

  Powell [@R52]                                      2014   45           larynx    FVT/PMF      0%             26%                                    

  Sayles[^\*^](#T5FN1){ref-type="table-fn"} [@R10]   2014   33 studies   larynx    Onlay flap   10%            28%                            0.001   (Chemo)radiotherapy

  Paleri[^\*^](#T5FN1){ref-type="table-fn"} [@R22]   2014   591          larynx                                                                       Pooled relative risk 0.63 (reduction one third compared to no flap)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Systematic review;

WC: wound complications, p: p-value, PMMF: pectoralis major myofascial flap, FVT: free vascularised tissue, PMF: pectoralis major flap, FRFF: free radial forearm flap, CRT: chemoradiotherapy.

Besides hypoalbuminaemia, neck dissection, comorbidities with diabetes mellitus or ischaemic heart disease, Tsoe et al. 8 found that reconstruction of the pharynx with primary closure had a statistically significant increased rate of fistula formation. On the contrary, Shemen et al. [@R24] and Herranz et al. [@R25] found an increase in complication rate when flap reconstruction was required. These patients had no history of radiation, and probably had a greater defect when a flap was required. Ganly et al. [@R26] found no association between wound complications and flap reconstruction or neck dissection. The only significant independent predictor found was chemoradiation. Other suggested potential predictors for increased wound complications and fistula are: postoperative haemoglobin level lower than 12.5 g/dl, albumin level less than 40 g/l, prior tracheotomy, preoperative radio- an/or chemotherapy, concurrent neck dissection, radical neck dissection, poor nutritional status, tobacco and excessive alcohol use, poor renal and hepatic function, radiotherapy doses in excess of 70 Gy, early removal of drains (within 3 days of operation), vacuum drain duration and surgery extended to the pharynx or hypopharynx cancer [@R11] [@R27]^-^[@R31]. We found more wound related complications in patients with current excessive alcohol use. This might be caused by immunosuppression due to ethanol, or alcohol-related lifestyle factors such as certain dietary deficiencies owing to unevenly composed diets [@R32].

Whether the interval between chemoradiotherapy and salvage surgery influences the risk of fistula formation remains uncertain. Increased incidence of wound complications was reported when the interval was shorter [@R23] [@R25] [@R33]. However, Lavertu et al. [@R34] and Weber et al. [@R35] found no significant difference between groups with short and longer interval between chemoradiation and salvage surgery. Inohara et al. [@R36] found no difference in complication incidence between salvage surgery for persistent or recurrent disease. We also did not find an association between interval and complication rate.

Comparing our results in patients with salvage laryngectomy: a) after previous radiotherapy in a previous study [@R15]; to b) after previous chemoradiotherapy in the present study, shows a worse 5-year prognosis for local disease control (58% *vs.* 70%) and overall survival (27% *vs.* 50%) in the chemoradiotherapy group. The total complication rate is 73% after chemoradiotherapy *vs.* 56% after radiotherapy.

The 5-year overall survival of 27% is comparable to other series, with a relatively better survival for patients with recurrent laryngeal carcinoma (compared to hypopharyngeal) or patients with a regional recurrence ([Table IV](#T4){ref-type="table"}). Even after adjusting for covariates, Goodwin [@R37] found that a history of chemotherapy was associated with poorer survival after salvage surgery, suggesting a more aggressive tumour biology [@R38]. Because of the low survival and high complication rates, the profit of salvage surgery is sometimes questioned. Salvage surgery is definitely worthwhile in a subset of patients. Reliable predictors for survival after salvage surgery are needed. Tan et al. [@R16] suggested a model with stage IV tumours and concurrent local and regional failures as independent negative predictors. Esteller et al. [@R18] found no significant differences in survival when analysed according to the classification of Tan. We found a worse survival for stage IV initial tumours. Other suggested potential predictors for a worse survival are: residual disease, older age, N3, positive resection margins and neck nodes with extranodal spread [@R18] [@R38] [@R39].

In this series age was an independent predictor for salvage surgery. Older patients were less frequently candidate for salvage surgery if recurrent tumour was diagnosed. Elderly patients with head and neck cancer generally have multiple and more severe comorbidity [@R40]. Comorbidity is associated with a higher complication rate and poorer survival after major surgery [@R41]^-^[@R43]. Selection of elderly patients based on comorbidity seems to be the explanation for the similar complication rate and survival after salvage surgery. Moreover, patients with severe comorbidity would not have been treated with chemoradiation in the first place and therefore not included in this study.

In conclusion, one third of the patients with local and/or regional disease after chemoradiation underwent salvage surgery. Most of the patients not suitable for salvage surgery had distant metastases. Forty percent of the laryngectomies needed a flap reconstruction to cover mucosal defects. Patients who were at forehand more prone to wound healing failures underwent reconstruction with a PM flap in the neck to prevent wound related complications. One in four patients developed a pharyngocutaneous fistula. Only current excessive alcohol use was associated with complications. No significant independent predictors of survival were identified. The 5-year overall survival rate was 27% after salvage surgery. Older patients with recurrent laryngeal or hypopharyngeal carcinoma after chemoradiation selected for salvage surgery have a similar complication and survival rate compared to younger patients.
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